Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
1 other identifier
interventional
16
0 countries
N/A
Brief Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jan 2004
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2005
CompletedFirst Submitted
Initial submission to the registry
April 18, 2008
CompletedFirst Posted
Study publicly available on registry
April 22, 2008
CompletedApril 22, 2008
April 1, 2008
April 18, 2008
April 18, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MMP levels
16 weeks
Interventions
spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
Eligibility Criteria
You may qualify if:
- chronic stable heart failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 18, 2008
First Posted
April 22, 2008
Study Start
January 1, 2004
Study Completion
December 1, 2005
Last Updated
April 22, 2008
Record last verified: 2008-04